Philips has announced the acquisition of SpectraWave, a medical technology company focused on next-generation coronary imaging and physiology solutions. The move is part of Philips’ broader strategy to embed artificial intelligence across cardiovascular care workflows and enhance real-time clinical insights in cath labs.

SpectraWave’s technology is designed to deliver detailed visualisation and physiological data during coronary interventions, allowing clinicians to assess vessel health, blood flow and lesion characteristics with greater clarity. By integrating these capabilities, Philips aims to support improved diagnostic confidence and procedural precision in interventional cardiology.

According to Philips leadership, the acquisition reinforces the company’s commitment to AI-driven precision medicine, where intelligent imaging and analytics help streamline workflows, reduce variability in care, and improve patient outcomes. The combined technologies are expected to support cardiologists from pre-procedure planning through real-time intervention and post-procedure evaluation.

The acquisition reflects a growing industry trend in which global MedTech leaders are investing in advanced imaging, data intelligence and AI platforms to address the rising burden of cardiovascular disease worldwide. With SpectraWave now part of its portfolio, Philips continues to strengthen its position in intelligent heart-care solutions.